# Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease

> **NCT07436767** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 3 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **GENETIC:** KL003 Cell Injection

## Key facts

- **NCT ID:** NCT07436767
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07436767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07436767, "Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07436767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*